Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 218   

Articles published

SNY 48.27 +0.72 (1.51%)
price chart
Regeneron Pharmaceuticals Inc And Sanofi SA (ADR) Win EU Nod For Cholesterol ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leader in the biotech sector, and Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, have fetched a victory adding to their success in the pharmaceutical sector.
Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA ...  Smarter Analyst
Healthcare Stocks News Recap- Sanofi SA (ADR) (SNY), Shire PLC (ADR) (SHPG ...  Techsonian (press release)
Google Inc, Sanofi SA (ADR) Partner Up For Diabetes Research
The Wall Street Journal has reported that Google Inc. (NASDAQ:GOOG) is going to partner up with European pharmaceutical giant Sanofi SA (NYSE:SNY) to research on monitoring and curing diabetes. While both the companies refused to disclose how ...
Google Inc (NASDAQ:GOOGL) team up with Sanofi SA for new techniques to ...  Wall Street Point
Google, Sanofi join forces on Diabetes monitoring and treatment  MarketWatch
Sanofi SA (ADR) Scouts For New Cancer Treatments That Harness Immune Cells
Pharmaceutical giant Sanofi is partnering with two biotech companies -- Evotec AG in Hamburg, Germany, and Apeiron Biologics AG in Vienna, Austria - in its latest effort to develop a drug that harnesses the body's own immune system in the fight against ...
Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Sanofi SA (ADR) And Regeneron Pharmaceuticals Inc Down With Praluent's Limited ...
Sanofi SA (NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have received recommendation of approval for Praluent, their new drug.
FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals  Benzinga
How Big of an Impact Could Praluent Have on Regeneron Pharmaceuticals Inc.?  Motley Fool
Amgen, Inc. Or Sanofi SA (ADR) - Who Will Rule The Cholesterol Market?
Amgen, Inc. (NYSE:AMGN) and Sanofi SA ADR (NYSE:SNY) are all set to change the cholesterol drug market with their powerful new treatments that belong to a new class of drugs called PCSK9 protein inhibitors.
Sanofi SA (ADR) Chief Strategy Officer Resigns; Company Facing Another Turmoil ...
Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, is facing another turmoil as its chief strategy officer, David-Alexandre Gros, has resigned only six months after the company's famous chief executive officer, Chris Viehbacher, was ousted by ...
Driven By Amgen, Inc. And Sanofi SA (ADR), US Drug Price War May Shift From ...
As per research presented at the annual meeting of the American College of Cardiology in March and conducted separately by Amgen, Inc. (NASDAQ:AMGN), and Sanofi SA (ADR) (NYSE:SNY) along with its development partner Regeneron Pharmaceuticals ...
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.